Randomized Embolization Trial for NeuroEndocrine Tumor Metastases to the Liver (RETNET): study protocol for a randomized controlled trial

Neuroendocrine tumors (NETs) are the second most common gastrointestinal malignancy after colon cancer. Up to 90% of patients with NETs develop liver metastases, which are a major determinant of symptoms and s...

Source: Trials - July 17, 2018 Category: General Medicine Authors: James X. Chen, E. Paul Wileyto and Michael C. Soulen Tags: Study protocol Source Type: research